ReviewAntibiotics (Basel, Switzerland)2025
Recent Advances in Endolysin Engineering.
Review in Antibiotics (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Targeted delivery of peptidoglycan hydrolases (PGH) via engineered extracellular vesicles (EVs) to clear intracellular bacterial infections.Materials today. Bio · 2026Article
- Polycationic Peptide Engineering of Phage Endolysins Expands Host Range and Enhances Antibacterial and Antibiofilm Activities Against Bacillus Species.Biotechnology and bioengineering · 2026Article
- Bacteriophages in the treatment of cutaneous infections and skin disorders: therapeutic advances and future directions.Clinical microbiology reviews · 2026Review
- Domain shuffling of endolysin LysKB317 to controlBiotechnology reports (Amsterdam, Netherlands) · 2026Article
- Evaluation of the Therapeutic Effect of a Bovine-DerivedMicroorganisms · 2026Article
- Construction and Characterization of the Novel Engineered Endolysin ALC005: A New Alternative Antimicrobial AgainstMicroorganisms · 2026Article
- Phage-Derived Endolysins TargetingAntibiotics (Basel, Switzerland) · 2026Review
- Data mining reveals the diversity of prophage endolysins targeting pathogenic enterococci.The Journal of general virology · 2026Article
- Novel Recombinant Endolysin LysMYM94 against Dry-Grind Corn Mash Bioethanol Fermentation Contaminant Limosilactobacillus fermentum.Probiotics and antimicrobial proteins · 2026Article
- Article
- Physicochemical and Proteolytic Barriers Limiting Activity of Cpl-1 and Pal Endolysins in Human Circulation.Current issues in molecular biology · 2026Article
- Comparative Combinatorial Effects of Endolysins LNT103 with Ten Conventional Antibiotics against Gram-Negative Bacterial Pathogens.Journal of microbiology and biotechnology · 2026Article
- A chimeric, half-life extended lysin with a unique mode of action.Frontiers in microbiology · 2026Article
- Advances in mycobacteriophage research: from lytic mechanisms to one health applications.Frontiers in cellular and infection microbiology · 2026Review
- Translational barriers to phage endolysin deployment for antimicrobial resistance control in Africa.Frontiers in antibiotics · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Antimicrobial resistance threatens a new "dark age" in medical practice. Chronic antibiotic overuse has driven the rise in antimicrobial resistance and promoted the emergence of multidrug-resistant organisms. To address this problem, researchers have developed new approaches. Antimicrobials derived from bacteriophage, which are viruses that target bacteria, are promising candidates. Amongst these candidates, bacteriophage enzymes used in the viral replication cycle are of significant interest. Specifically, endolysins are used by bacteriophage to lyse the bacterial cell wall, leading to structural collapse and cell lysis. Researchers are increasingly applying these proteins externally to multidrug-resistant organisms as a novel antimicrobial treatment. Following this increased interest, many studies have presented protein engineering methods to further enhance the effectiveness of endolysins as antimicrobials. These methods include attachment of membrane-permeabilizing peptides, domain-swapping, and catalytic-site modification. Recent advances in all three fields have seen the implementation of tools like novel in silico design pipelines and library-based screening methods. This review summarizes these recent advances in the rapidly developing field of endolysin engineering and discusses potential future directions in this field.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.